Indicated for: type 2 diabetes mellitus
Route of administration: oral
Substance: empagliflozin (SGLT2 inhibitor)
ATC: A10BK03 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sodium-glucose co-transporter 2 (SGLT2) inhibitors)
Empagliflozin is a medication used to treat type 2 diabetes. It belongs to the class of SGLT2 inhibitors (sodium-glucose co-transporter 2) and works by lowering blood sugar levels through the elimination of excess glucose in the urine. It is typically used in combination with other antidiabetic medications or as monotherapy when other treatments are not suitable.
Empagliflozin not only helps control blood sugar levels but also provides additional cardiovascular benefits. Studies have shown that this medication reduces the risk of death from cardiovascular causes in patients with type 2 diabetes and pre-existing cardiovascular disease. It can also help reduce the risk of heart failure.
The medication is taken as oral tablets, usually once daily, regardless of meals. It is important for patients to follow their doctor’s instructions and regularly monitor blood sugar levels to assess the effectiveness of the treatment.
Empagliflozin is generally well-tolerated, but side effects such as urinary tract infections, genital infections, or dehydration may occur. In rare cases, it can cause diabetic ketoacidosis, a serious condition that requires immediate medical attention.
This medication is not indicated for patients with type 1 diabetes or severe renal impairment. It is important for patients to maintain a healthy lifestyle, including a balanced diet and regular exercise, to maximize the benefits of the treatment.